Stryker Corporation reported its fourth-quarter earnings for 2024, revealing an adjusted earnings per share (EPS) of $4.01, surpassing analysts' expectations of $3.87. The company also noted a 10.7% increase in net sales, which reached $6.4 billion, slightly above the anticipated $6.36 billion. The MedSurg and Neurotechnology segments contributed $3.9 billion in net sales, exceeding estimates of $3.77 billion. For the fiscal year 2025, Stryker anticipates an adjusted EPS range of $13.45 to $13.70, with an expected organic net sales growth of 8% to 9%. The reported operating income margin stood at 9.0%, while the adjusted operating income margin improved by 200 basis points.